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Introduction:
• Interleukin-1 inhibitors are immunosuppressive drugs that target the
proinflammatory cytokines IL-1α and IL-1beta.

• IL-1 inhibitors can be used to treat various rheumatologic disorders
• The three available IL-1 inhibitors are anakinra, canakinumab and
rilonacept

• Although there are a few reports implicating IL-1 inhibitors as
causes of inflammatory bowel disease (IBD), this is not a wellestablished adverse effect

• The FDA Adverse Event Reporting System (FAERS) is a publicly
available database for post-marketing surveillance of drug safety

Objectives:
• Evaluate FAERS reports to examine the possible relationship
between incidence of de novo IBD and treatment with IL-1 inhibitor
therapies for various rheumatologic conditions

Table 1. The Adverse Drug Reaction Probability Scale, also known as the
Naranjo scale. Cumulative scores were interpreted as definite (≥9),
probable (5-8), possible (1-4), or doubtful (≤0).

Figure 1. IL-1 Inhibitors and Naranjo Score for Possible Drug-Induced De Novo IBD. Anakinra and canakinumab are
represented by blue and orange bars, respectively.

Results:
• Of the 34 cases of IBD reported in patients from IL-1 inhibitor therapy, 6 were excluded because

Methods:

patients had a prior history of IBD

• There were 12 reports of IBD from anakinra. Based on the Naranjo scale, 11 were possible

• All FAERs reports for patients receiving anakinra, canakinumab or

anakinra-induced IBD and 1 was a doubtful case.

rilonacept were investigated

• There were 18 reports of canakinumab-induced IBD. Based on the Naranjo scale 17 were possible

• Only “primary suspect” reports of IBD as an adverse event were

canakinumab-induced IBD and one was a probable case.

selected

• There were no reports linking rilonacept therapy to IBD in the FAERs database (Table 2, Figure 1)

• Subsequently, files were queried for inflammatory bowel disease,
Crohn’s disease and ulcerative colitis as reaction terms

Conclusions:

• Detailed reports of these cases were requested from the FDA
• The Adverse Drug Reaction Probability Score, (Naranjo Scale), was

• Review of the collected FAERS reports suggests a possible causal relationship between treatment

applied to each case to assess the likelihood of a causal
relationship between the IL-1 inhibitor and the adverse effect of de
novo IBD (see Table 1)

with IL-1 inhibitors and de novo IBD

• These results are significant, as the underlying pharmacodynamics of these medications may

• The probability of the drug reaction is assigned via a score for a

either unmask or initiate IBD in these patient populations being treated for various rheumatologic
disorders

definite (≥9), probable (5-8), possible (1-4) or doubtful (≤0) reaction

• Further investigation of the mechanisms driving the development of IBD in patients on IL-1 inhibitor
Table 2. Results of Naranjo Score by Individual Report to FAERS

therapy is needed.

